Clinical trials: Lipid Disorders
Hypercholesterolemia
Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)
Primary Objective: To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by a regimen of Alirocumab including a starting dose of 150 mg every 4 weeks (Q4W) as add-on to non-statin lipid modifying background…
- Trial name
- NCT02023879
- Testing
- Alirocumab, Non-statin LMT, Diet Alone
- Where
- 43 sites in United States, Australia and 6 more
- Volunteers
- 233 people
- Sponsor
- Sanofi
Type IIa and IIb Hypercholesterolaemia
Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients
The purpose of this study is to evaluate the efficacy and safety of Rosuvastatin 5 mg as an hypercholesterolemia treatment comparatively at 2 other statins: Pravastatin 40 mg and Atorvastatin 10 mg.
- Trial name
- CAP-Chol (NCT00631189)
- Testing
- Rosuvastatin, Pravastatin, Atorvastatin
- Where
- 170 sites in France
- Volunteers
- 668 people
- Sponsor
- AstraZeneca
Gaucher Disease, Type 1 Gaucher Disease
A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease
This study evaluated the safety and tolerability of afegostat tartrate in participants with type 1 Gaucher disease who were not receiving enzyme replacement therapy (ERT) or substrate reduction therapy (SRT).
- Conditions
- Gaucher Disease, Type 1 Gaucher Disease, Gaucher Disease, Type 1
- Trial name
- NCT00446550
- Testing
- afegostat tartrate
- Where
- 11 sites in United States, Israel and 2 more
- Volunteers
- 19 people
- Sponsor
- Amicus Therapeutics
Gaucher Disease, Type 1
A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease
Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to this deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular…
- Trial name
- NCT00430625
- Testing
- VPRIV ®,
- Where
- 5 sites in Argentina, Israel and 3 more
- Volunteers
- 25 people
- Sponsor
- Shire
Hypercholesterolemia
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
- Trial name
- ODYSSEY MONO (NCT01644474)
- Testing
- Alirocumab, Ezetimibe
- Where
- 8 sites in United States, Belgium and 2 more
- Volunteers
- 103 people
- Sponsor
- Sanofi
Severe Hypertriglyceridemia, Mixed Dyslipidaemia
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)
- Trial name
- INDIGO-1 (NCT02944383)
- Testing
- Gemcabene
- Where
- 49 sites in United States, Canada
- Volunteers
- 91 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Dyslipidemias, High Cholesterol
Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct…
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia
- Trial name
- ROSE2 (NCT05266586)
- Testing
- Obicetrapib, Ezetimibe 10mg
- Where
- 16 sites in United States
- Volunteers
- 119 people
- Sponsor
- NewAmsterdam Pharma
Hypertriglyceridemia
Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia
Pharmacodynamic effects of MAT9001 compared to Vascepa in adults with hypertriglyceridemia
- Trial name
- ENHANCE-IT (NCT04177680)
- Testing
- Omega 3 pentaenoic acid, icosapent ethyl
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Metabolic Syndrome
P20 Extending Sleep to Reverse Metabolic Syndrome
This pilot study will test the acceptability and feasibility of a sleep extension intervention in community-dwelling, short-sleeping, racially/ethnically diverse middle-aged adults with MetS.
- Trial name
- NCT03596983
- Testing
- Sleep Intervention, Week 2 Intervention
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- NYU Langone Health
Diabetes Mellitus
Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with metformin in adults with type 2 diabetes mellitus.
- Trial name
- NCT00286442
- Testing
- Alogliptin and metformin, Metformin
- Where
- 56 sites in United States, Argentina and 15 more
- Volunteers
- 527 people
- Sponsor
- Takeda
Obesity, Insulin Resistance
Study of the Relationship Between Body Composition, Insulin Resistance and HDL Levels
Approximately 20 million people in the United States have some form of kidney failure. People with kidney failure have an increased chance of having low levels of high density lipid (HDL), so called "good cholesterol." Patients…
- Trial name
- NCT02755818
- Testing
- Heparin
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Fabry Disease
Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)
This is the first in human treatment with ST-920, an adeno-associated virus (AAV2/6) vector encoding the complementary deoxyribonucleic acid (cDNA) for human a-Gal A.
- Trial name
- NCT04046224
- Testing
- ST-920
- Where
- 18 sites in United States, Australia and 5 more
- Volunteers
- 36 people
- Sponsor
- Sangamo Therapeutics
Hypercholesterolemia
Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)
Evaluate the safety of the long-term (1 year) coadministration of ezetimibe and simvastatin in patients with hypercholesterolemia who have not reached low density lipoprotein (LDL)-cholesterol target with…
- Trial name
- NCT00653523
- Testing
- Ezetimibe, Simvastatin
- Volunteers
- 151 people
- Sponsor
- Organon and Co
Coronary Artery Disease
Evaluation of a Combined Near Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) Catheter for Detection of Lipid Rich Plaque
The purpose of this study is to learn more about lipid rich plaque using Near Infrared Spectroscopy (NIRS)/Intravascular Ultrasound (IVUS) imaging in patients who have had coronary artery stenting and Optical coherence tomography…
- Trial name
- NCT01506960
- Testing
- InfraReDx Lipiscan IVUS
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Massachusetts General Hospital
Type 1 Hyperlipoproteinemia
Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia
Funding Source - FDA OOPD This study is being done to find out whether an investigational (not approved by FDA ) drug called SLx-4090 or Orlistat (FDA approved medication for weight loss) when given alone or in combination can…
- Trial name
- NCT01675154
- Testing
- Orlistat, Slx-4090
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- University of Texas Southwestern Medical Center
Alzheimer's Disease, Oxidative Stress
Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease
The purpose of this study is to determine the effect of fish oil and the antioxidant alpha lipoic acid on factors in the blood that are associated with the progression of Alzheimer's Disease (AD).
- Conditions
- Alzheimer's Disease, Oxidative Stress, Dementia, Hyperlipidemia
- Trial name
- NCT00090402
- Testing
- Fish Oil, Lipoic Acid
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Oregon Health and Science University
Lipodystrophy
Short-term Effects of Leptin in People With Lipodystrophy
Background: Lipodystrophy is a condition where people do not have enough fat in the body. People with lipodystrophy can have problems such as diabetes or an enlarged liver.
- Trial name
- NCT01778556
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Skin Laxity, Lipodystrophy
CONFORM: Rotational Fractional Resection for Submental Contouring
This study will evaluate the safety and efficacy of rotational fractional resection (RFR) to improve neck contouring. RFR is used to remove loose skin and fat.
- Trial name
- NCT03407313
- Testing
- Rotational fractional resection (1.5mm diameter device)
- Where
- 6 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Recros Medica, Inc.
Dyslipidemia, HIV Infections
Preliminary Study of Safety and Efficacy of Policosanol
Lay Language Summary: High cholesterol levels are common in persons with HIV infection. However, conventional cholesterol-lowering medications may have harmful side effects when given to HIV-infected persons.
- Trial name
- NCT00312923
- Testing
- Policosanol
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Rush University Medical Center
Fabry Disease
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
This is an exploratory study to evaluate changes in glycosphingolipid levels and other (exploratory) Fabry disease parameters in male Fabry disease participants who were previously treated with agalsidase alfa (Replagal®) 0.2…
- Trial name
- NCT01650779
- Testing
- Agalsidase beta
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Genzyme, a Sanofi Company